StockData
Oruka Therapeutics, Inc. logo

Oruka Therapeutics, Inc. (ORKA) stock

ORKANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$96.32−2.92 (-2.94%)

Close on Nov 17, 2026Market cap $6.38BP/E –Yield –

Oruka Therapeutics cash

Cash and short-term investments held at the end of each period.

Oruka Therapeutics's cash was $873.56M at Jun 30, 2026. For fiscal 2025 it was $337.04M, down 10.3% from the year before. Over ten years it grew 24.1% a year on average. The highest annual figure on record is $375.65M in fiscal 2024.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$337.04M-10.3%
FY2024Dec 31, 2024$375.65M+903.6%
FY2023Dec 31, 2023$37.43M-11.8%
FY2022Dec 31, 2022$42.45M-20.5%
FY2021Dec 31, 2021$53.36M+8.7%
FY2020Dec 31, 2020$49.07M+486.8%
FY2019Dec 31, 2019$8.36M+26.6%
FY2018Dec 31, 2018$6.61M-43.8%
FY2017Dec 31, 2017$11.75M-44.5%
FY2016Dec 31, 2016$21.16M-45.5%
FY2015Dec 31, 2015$38.80M+152.7%
FY2014Dec 31, 2014$15.35M-8.4%
FY2013Dec 31, 2013$16.76M+473.8%
FY2012Dec 31, 2012$2.92M-50.9%
FY2011Dec 31, 2011$5.94M-15.4%
FY2010Dec 31, 2010$7.03M-9.5%
FY2009Dec 31, 2009$7.76M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$873.56M+166.0%
Q1 FY2026Mar 31, 2026$388.83M+11.4%
Q4 FY2025Dec 31, 2025$337.04M-10.3%
Q3 FY2025Sep 30, 2025$349.16M-15.0%
Q2 FY2025Jun 30, 2025$328.41M+2071.9%
Q1 FY2025Mar 31, 2025$349.09M+1158.3%
Q4 FY2024Dec 31, 2024$375.65M+903.6%
Q3 FY2024Sep 30, 2024$410.88M+967.6%
Q2 FY2024Jun 30, 2024$15.12M-62.3%
Q1 FY2024Mar 31, 2024$27.74M-32.1%
Q4 FY2023Dec 31, 2023$37.43M-11.8%
Q3 FY2023Sep 30, 2023$38.49M-12.4%
Q2 FY2023Jun 30, 2023$40.16M-13.5%
Q1 FY2023Mar 31, 2023$40.85M-16.7%
Q4 FY2022Dec 31, 2022$42.45M-20.5%
Q3 FY2022Sep 30, 2022$43.94M-24.6%
Q2 FY2022Jun 30, 2022$46.44M-26.5%
Q1 FY2022Mar 31, 2022$49.06M-26.7%
Q4 FY2021Dec 31, 2021$53.36M+8.7%
Q3 FY2021Sep 30, 2021$58.31M+14.1%
Q2 FY2021Jun 30, 2021$63.20M+846.9%
Q1 FY2021Mar 31, 2021$66.93M+700.3%
Q4 FY2020Dec 31, 2020$49.07M+408.8%
Q3 FY2020Sep 30, 2020$51.10M+412.7%
Q1 FY2020Mar 31, 2020$6.67M-16.6%
Q4 FY2019Dec 31, 2019$8.36M+26.6%
Q3 FY2019Sep 30, 2019$9.65M+19.7%
Q2 FY2019Jun 30, 2019$9.97M+3.4%
Q1 FY2019Mar 31, 2019$8.01M-33.8%
Q4 FY2018Dec 31, 2018$6.61M-43.8%
Q3 FY2018Sep 30, 2018$8.06M-49.5%
Q2 FY2018Jun 30, 2018$9.64M-39.8%
Q1 FY2018Mar 31, 2018$12.10M-37.0%
Q4 FY2017Dec 31, 2017$11.75M-44.5%
Q3 FY2017Sep 30, 2017$15.95M-32.0%
Q2 FY2017Jun 30, 2017$16.01M-39.3%
Q1 FY2017Mar 31, 2017$19.21M–
Q4 FY2016Dec 31, 2016$21.16M–
Q3 FY2016Sep 30, 2016$23.47M–
Q2 FY2016Jun 30, 2016$26.36M–

More Oruka Therapeutics figures

See a number that looks wrong?